EPO and anemia (phenotype): Regarding the safety of triple therapy for cirrhotic patients, in the ANRS CO20 CUPIC study [16], although the early discontinuation rate within 16 weeks was 11.7%, a high incidence of serious adverse events (40%), death (1.2%), severe complications (severe infection or hepatic decompensation; 6.4%), and difficult management of anemia (requiring erythropoietin and transfusion) were observed.